Compare Keysight Technologies Inc (KEYS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs ResMed Inc. — how do they compare? Keysight Technologies Inc trades at $382.61 (market cap $63.79B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Keysight Technologies Inc is far larger — about 2× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and ResMed Inc. for 51 Days on average.
| KEYS | RMD | |
|---|---|---|
Market Cap | $63.79B | $31.89B |
Volume | 1,435,384 | 618,314 |
Sector | Technology | Health |
52-Week High | $387.90 | $275.96 |
52-Week Low | $159.49 | $182.82 |
Typical Hold Time | 56 Days | 51 Days |
Enterprise Value | $63.93B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KEYS trades at $374.66, down 1.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $3.07 exceeding the $2.48 forecast. The company is capitalizing on AI infrastructure and 6G development, as highlighted by a 56% surge in Q3 orders. Valuation ratios are elevated, with a P/E of 50.7 and P/S of 9.85, reflecting high growth expectations.
The outlook is positive, driven by robust AI and 6G demand, but risks include supply constraints and rich valuations. The consensus price target of $416.63 implies significant upside, supported by 13 buy ratings. However, execution risks and market volatility could pressure the stock if growth momentum slows.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
